Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer-Reference-Cited by-同舟云学术

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

Published:2010-07-22 Issue:2 Volume:123 Page:463-469
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Wildiers H.,Fontaine C.,Vuylsteke P.,Martens M.,Canon J. L.,Wynendaele W.,Focan C.,De Greve J.,Squifflet P.,Paridaens R.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-010-1066-x.pdf

Reference22 articles.

1. Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26(11):1810–1816

2. George S, Blay JY, Casali PG et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45(11):1959–1968

3. Gennari A, Amadori D, De LM et al (2006) Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24(24):3912–3918

4. Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592

5. Davidson NG (1996) Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol 23(5 Suppl 11):6–10

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Toxicity Risks of Sunitinib in Cancer Patients: A Meta-Analysis;J BIOL REG HOMEOS AG;2023

2. Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions;Current Topics in Medicinal Chemistry;2022-04

3. Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies;Cancer Letters;2021-11

4. Risk of Thrombocytopenia With Platelet‐Derived Growth Factor Receptor Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta‐Analysis of Phase 2/3 Randomized, Controlled Trials;The Journal of Clinical Pharmacology;2021-08-02

5. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence;Breast Cancer Research;2020-09-29